Luz, M. D. A., Briganti, A., Murphy, D., Pieczonka, C. M., Suzuki, H., Yu, E. Y., Artignan, X., Gotto, G., Hamilton, J., Malone, R. J., Adorjan, P., Ghadessi, M., Verholen, F., Armstrong, A. J. (2026). Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.99